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Symptomatic intracranial atherosclerotic disease (ICAD) is responsible for approximately 10% 
of all ischemic strokes in the United States. The risk of recurrent stroke may be as high as 35% 
in patient with critical stenosis >70% in diameter narrowing. Recent advances in medical and 
endovascular therapy have placed ICAD at the forefront of clinical stroke research to optimize 
the best medical and endovascular approach to treat this important underlying stroke etiology. 
Analysis of symptomatic ICAD studies lead to the question that whether angioplasty and/or 
stenting is a safe, suitable, and efficacious therapeutic strategy in patients with critical stenoses 
that are deemed refractory to medical management. Most of the currently available data in 
support of angioplasty and/or stenting in high risk patients with severe symptomatic ICAD is 
in the form of case series and randomized trial results of endovascular therapy versus medical 
treatment are awaited. This is a comprehensive review of the state of the art in the endovascular 
approach with angioplasty and/or stenting of symptomatic ICAD.
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 recurrent stroke in the symptomatic vascular territory at 1 year on 
aspirin or warfarin, respectively, and 17–20% at 2 years (Chimowitz 
et al., 2005). Patients with 70–99% stenosis had a recurrent stroke 
risk of 18% at 1 year compared to patients with 50–69% who had 
a 7% risk of stroke at 1 year (Kasner et al., 2006). Additionally, time 
from qualifying event (≤17 days) predicted risk of recurrent stroke 
(Kasner et al., 2006). Furthermore patients with intracranial stenosis 
who fail antithrombotic therapy were not at a higher risk for stroke 
than those who did not fail antithrombotic therapy (Turan et al., 
2009). All of these analyses lead to the question that in patients 
with symptomatic severe ICAD defined as ≥70% stenosis is angi-
oplasty and/or stenting a safe, effective, and viable treatment option? 
Currently, there is no data from a randomized controlled trial to 
guide clinicians toward an endovascular treatment of ICAD related 
ischemic strokes. Additionally there are no specific recommenda-
tions in the American Heart Association (AHA)/American Stroke 
Association (ASA) guidelines (Adams et al., 2008) for treatment or 
secondary prevention from ICAD related ischemic stroke. Most of 
the data currently available supporting angioplasty and stenting of 
ICAD is in the form of case series and there is no Level 1 evidence 
available to support endovascular therapy over medical manage-
ment. The ongoing stenting and aggressive medical management for 
preventing recurrent stroke in intracranial stenosis (SAMMPRIS) 
trial is a randomized controlled trial that should help determine if 
intracranial stenting is superior to best medical management for 
symptomatic ICAD of 70–99% (Derdeyn and Chimowitz, 2007).
The endovascular treatment of symptomatic ICAD has 
evolved with advances in technology. Originally balloons 
and stents designed for the coronary vasculature were used. 
IntroductIon
Symptomatic intracranial atherosclerotic disease (ICAD) is respon-
sible for approximately 10% of all ischemic strokes in the United 
States (Sacco et al., 1995; Qureshi et al., 2003). The prevalence of 
ICAD related ischemic stroke is higher in African American (17%) 
and Hispanics (13%) than among white Americans (9%); however, 
it is highest in the Chinese population (33–37%; Huang, 1997; 
Wong et al., 1998; White et al., 2005). Independent risk factors 
for ICAD are age, hypertension, and diabetes mellitus (Bae et al., 
2007). Total serum cholesterol, HDL, and LDL may also be a risk 
factors for developing ICAD (Kostner et al., 1986; Suwanwela et al., 
2006). Risk factors for recurrent ischemic stroke from ICAD include 
hypertension (systolic ≥ 140 mmHg), hyperlipidemia (≥200 mg/
dl), no alcohol consumption, and diabetes mellitus (Wong, 2003; 
Chaturvedi et al., 2007). Men may have a higher risk for developing 
ICAD particularly at younger ages (Passero et al., 1987; Moossy, 
1993), but women appear to have a higher recurrent risk (Kasner 
et al., 2006). Angiotensin converting enzyme polymorphisms, 
plasma endostatin/vascular endothelial growth factor ratio, glu-
tathione S-transferase omega-1 gene polymorphism, and plasma 
homocysteine levels are non-modifiable risk factors noted to be 
associated with ICAD. Sickle cell disease is an uncommon risk factor 
that can also be managed to reduce the risk of stroke. Associations 
of ICAD with diabetes mellitus, metabolic syndrome, Alzheimer’s 
disease, aortic plaques, radiotherapy, and meningitis are less well 
documented (Suri and Johnston, 2009).
In the comparison of warfarin and aspirin for symptomatic 
intracranial arterial stenosis (WASID) trial, patients with symp-
tomatic 50–99% intracranial stenosis had 12 and 11% risks of 
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stroke). Two patients had strokes in the territory of angioplasty at 
2 and 37 months after angioplasty. The annual stroke rate in the 
territory appropriate to the site of angioplasty was 3.4%, and for 
those patients with a residual stenosis of ≥50% it was 4.5%.
A Cochrane review of 79 articles (a total of 1999 cases) consist-
ing of open-label case series with three or more cases of primary 
angioplasty was published in 2006 (Cruz-Flores and Diamond, 
2006). The safety profile of the procedure showed an overall peri-
operative rate of stroke of 7.9%, perioperative death of 3.4%, and 
perioperative stroke or death of 9.5%. Of these studies with a 1-year 
follow-up the stroke rate at 1 year was 6%.
All these descriptive studies show that the procedure is feasi-
ble though it carries a significant morbidity and mortality risk. 
Technical disadvantages such as dissection of the artery, vessel 
occlusion, immediate elastic recoil, and higher restenosis rates cou-
pled with the vast amount of data from the coronary literature has 
rendered a somewhat inferior impression of balloon angioplasty 
alone compared to angioplasty with stenting; however, that being 
said the two modalities have not been compared head to head pro-
spectively. Evidence from randomized controlled trials is needed 
to assess the safety of primary angioplasty and its effectiveness in 
preventing recurrent stroke.
IntracranIal angIoplasty and stent placement
Currently data exists for three different categories of stents in the treat-
ment of ICAD: balloon expandable bare metal stents (BEBMS), drug-
eluting balloon expandable stents, and self-expanding stents. Stent 
systems can also be divided into those that are primarily designed for 
the coronary vasculature (Table 1) and those that have been specifi-
cally designed for the intracranial vasculature (Table 2).
Balloon expandaBle Bare metal stents
Primary angioplasty without stent placement was occasionally 
complicated by dissection, acute vessel closure, and embolization 
(Higashida et al., 1993; Terada et al., 1996; Callahan and Berger, 
1997; Takis et al., 1997; Volk et al., 1997; Conners and Wojak, 1999; 
Marks et al., 1999). Initially, BEBMS were used to an acute vessel 
dissection after angioplasty of a ICAD lesion; however, many of the 
coronary stents were rigid making them difficult to navigate into the 
intracranial circulation (Dorros et al., 1998). Several coronary stents 
were found to be sufficiently flexible to track into the intracranial 
circulation including the Gianturco–Rubin-2 stent (Phatouros 
et al., 1999), Palmaz–Schatz stent (Dorros et al., 1998), and the 
Arterial Vascular Engineering stent series which included the AVE 
S670stend and Guidant Tetramultilink stent (Morris et al., 1999; 
Phatouros et al., 1999).
Mori et al. (1999, 2000) treated 10 patients with 12 intracranial 
occlusive lesions with flexible BEBMS; however 2 lesions were not 
accessible. In six of eight vertebrobasilar and two distal internal 
carotid artery lesions GFX stents (Medtronics, Santa Rosa, CA, 
USA) were successfully deployed. Two distal internal carotid artery 
lesions were successfully stented with Multilink coronary stents 
(Guidant/Vascular Intervention, CA, USA). In the 10 lesions suc-
cessfully treated, a pre-stent stenosis of 80% was reduced to 7%. 
No periprocedural complications occurred and no ischemic events 
were reported in 11 months of follow-up. At 3 months all patients 
had follow-up angiograms which showed no restenosis.
Recently, stents designed specifically for the intracranial vas-
culature and the treatment of ICAD have been approved and 
are being used.
For the purpose of this review a literature search was performed 
using the keywords of intracranial angioplasty and/or stenting 
and cases series were identified in which either both or one of 
the modalities was used to treat symptomatic ICAD. We subse-
quently divided this review into categories based on the modality 
used either angioplasty and/or stenting and within the latter have 
reviewed the different stent types currently available.
endovascular treatment of Icad
prImary IntracranIal angIoplasty
Early studies with intracranial percutaneous transluminal angi-
oplasty (PTA) reported a high risk of intraprocedural vessel rup-
ture, vasospasm, dissection, or death in up to 33% of patients 
(Higashida et al., 1993; Terada et al., 1996; Callahan and Berger, 
1997; Takis et al., 1997; Volk et al., 1997; Conners and Wojak, 1999; 
Marks et al., 1999). Angioplasty for symptomatic intracranial ste-
nosis was first reported by Sundt et al. (1980). Subsequently several 
groups have reported successful PTA for ICAD defined as <50% 
residual stenosis, with few complications in retrospective case 
series. Marks et al. (1999) reported 23 patients treated with PTA 
for symptomatic ICAD. Angioplasty resulted in reduced stenosis 
in 21 of 23 patients treated. In one patient, the lesion could not be 
crossed safely, and in the other patient balloon dilatations resulted 
in vessel rupture and death. During 3 years of follow-up the annual 
stroke rate was 3.2%. Conners and Wojak (1999) have also reported 
a 9-year retrospective analysis of PTA for ICAD related ischemic 
stroke. Slower balloon inflation combined with balloon under-
sizing resulted in reduced complications, but occasionally yielded 
suboptimal angiographic results. Oversized balloons with rapid 
inflation were used in 12 patients and 9 of those patients (75%) 
had angiographic dissections with 1 patient dying from a vessel 
occlusion. In comparison 50 patients were treated with undersized 
balloons and slower inflation times with a 14% risk of dissection 
all of which were asymptomatic.
Callahan and Berger (1997) treated 15 patients with ICAD 
related stroke who had failed warfarin therapy. Dilation was suc-
cessful in all vessels, with residual stenosis averaging <30%; how-
ever, one patient died secondary to vessel rupture and another 
suffered an ischemic stroke in the pons secondary to perforator 
compromise. Residual stenosis occurred in 16% with no stenosis 
measuring over 70%. Late restenosis occurred in 9% and were suc-
cessfully retreated. One guidewire perforation occurred resulting 
in the death of a patient. Nasher et al. (2000) reported 20 patients 
treated with PTA for vertebrobasilar stenosis. Success rate was 86% 
with complete resolution of posterior circulation symptoms. One 
patient had an ischemic stroke during the procedure. There was a 
14% rate of restenosis over 3–18 months.
A retrospective study was done to evaluate 36 patients with 
37 symptomatic atherosclerotic intracranial stenosis who under-
went primary balloon angioplasty after failing medical manage-
ment (Marks et al., 2005). Thirty-four patients were available for 
 follow-up at a mean of 53 months. The mean pretreatment stenosis 
was 84% before angioplasty and 43% after angioplasty. The peripro-
cedural death and stroke rate was 8.3% (two deaths and one minor 
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inferior cerebellar artery (PICA)] were treated. In the SSYLVIA 
study, the NEUROLINK System (Guidant Corporation) was used. 
It was specifically designed for navigating intracranial vasculature 
by having only a few links connect the rings, rendering the stent 
flexible enough to navigate tortuous intracranial vessels. In the first 
30 days, 6.6% had ischemic strokes and no deaths occurred. Of the 
55 intracranial lesions treated 33 had stenosis measuring 70–99% 
of which one patient had a stroke within the 30-day period. After 
30 days, 7.3% of patients had recurrent ischemic strokes. Successful 
stent placement was achieved in 95% of cases. At 6 months, rest-
enosis of ≥50% occurred in 32.4% intracranial arteries and 42.9% 
extracranial vertebral arteries. Thirty-nine percent of patients with 
recurrent stenoses were symptomatic. Post-procedure stenosis 
>30%, parent vessel diameter, and diabetes mellitus were all fac-
tors linked to restenosis. The NEUROLINK system however was not 
marketed past the trial as Guidant disbanded its neurovascular unit. 
Nevertheless this trial provided valuable data about the safety of 
stenting in the treatment of ICAD. Different from the prior BEBMS 
the NEUROLINK had been specifically designed with the intracra-
nial vasculature in mind. Since its discontinuation there until very 
recently were no other BEBMS for ICAD. Micrus Corporation® 
(San Jose, CA, USA) most recently has designed the Pharos Vitesse 
Chrome Cobalt BEMS that is under study in Europe.
Gomez et al. (2000) treated 12 patients with symptomatic basilar 
artery stenosis with flexible BEBMS coronary stents (Microstent II 
or GFX, Advanced Vascular Engineering, Inc. or Multilink Duet, 
Guidant, Inc.). Stenosis was reduced from an average of 71–10%. 
There were no deaths, stent thromboses, perforations, ruptures, or 
myocardial infarctions. One patient had non-specific symptoms, 
and another had a transient ischemic attack at a mean follow-up 
of 5.9 months.
Mazighi et al. (2008) retrospectively reviewed 53 consecutive 
symptomatic patients with 69 intracranial arterial lesions who were 
treated with coronary BEBMS. The technical success rate was 98.6%, 
with a reduction of the median percent stenosis from 85 to 0%. 
Stents were placed in 76.8%. The 30-day death or stroke rate was 
10.1% with one death. With a median follow-up of 24 months, the 
transient ischemic attack or stroke rate reached 5.8%. The restenosis 
rate at 1 year was 15.9% and was symptomatic in two patients.
The stenting of symptomatic atherosclerotic lesion in the ver-
tebral or intracranial arteries (SSYLVIA) was a non-randomized, 
multicenter feasibility study that enrolled 61 patients with symp-
tomatic disease (SSYLVIA Study Investigators, 2004). Forty-three 
patients with intracranial arteries (15 internal carotid, 5 mid-
dle cerebral, 1 posterior cerebral, 17 basilar, 5 vertebral) and 18 
extracranial vertebral arteries [6 ostia, 12 proximal to the posterior 
Table 1 | Summary of coronary stent studies used for treatment of intracranial stenosis.
Study Type Subjects 30-day outcomes Long-term outcomes Restenosis rates
Mori et al. (2000) Retrospective 10 No stroke or death No ischemic events at 11 months No restenosis at 3 months
Gomez et al. (2000) Retrospective 12 No stroke or death 2 patients had a TIA at 6 months 2/12 had F/U, 1 had basilar 
     occlusion at 4 months
Mazighi et al. (2008) Retrospective 53* 10% stroke or death 6% TIA or stroke at 2 years 16% at 1 year
Abou-Chebl et al. (2005)** Retrospective 8 1 patient had TIA No stroke or TIAs at 11 months No restenosis at 10 months
Qureshi et al. (2006)** Retrospective 18 1 stroke, no deaths 22% at 14 months 14% at 14 months
Gupta et al. (2006)** Retrospective 26 of 29 12% stroke or 5% stroke at 4 months 5% at 4 months 
  attempted dissection
Steinfort et al. (2007)** Retrospective 13 8% stroke 8% stroke at 11 months 9/12 had F/U with 0% 
     at 5 months
Natarajan et al. (2010)*** Retrospective 6 17% stroke 0% at 4–10 months 0% at 6 months
*Only 76% of patients were treated with stents.
**Studies using drug-eluting stents.
***Second generation drug-eluting stent.
Table 2 | Symptomatic intracranial atherosclerosis studies using stents designed for intracranial use.
Study Type Subjects 30-day outcomes Long-term outcomes Restenosis rates
SSYLVIA (2004) Prospective,  61 7% stroke, no deaths 7% after 30 days at 6 months 32% intracranial,  
 single arm    43% extracranial
Bose et al. (2007) Prospective,  45 5% ipsilateral stroke/death 7% ipsilateral stroke or 3/40 patients studied had 
 single arm   death at 6 months asymptomatic restenosis
Fiorella et al. (2007) Prospective 78 6% stroke/death Not reported 30%* at 6 months
  82 lesions   
Zaidat et al. (2008) Registry 129 10% stroke/death 14% stroke/death at 30 days or 25% at 5 months 
    ipsilateral stroke at 6 months
*Reported by Levy et al., (2007).
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symptomatic ICAD who had ≥50% stenosis where included. The 
Wingspan stent system was used in all patients and consists of self-
expanding nitinol stent preloaded in a delivery catheter and a sepa-
rately packaged Gateway PTA balloon catheter (Boston Scientific 
Corp; Figure 1). The 30-day composite ipsilateral stroke or death 
rate was 4.5%, and 7% at 6 months. The degree of stenosis was 
reduced from an average of 75–32%. Three patients had restenosis 
of ≥50% but were not symptomatic. There were no procedural in-
stent thromboses or parent vessel dissections or perforations.
Subsequently the real life experience of this system has been 
recorded in two prospective registries. In the US Multicenter 
Experience with the Wingspan Stent System for the Treatment of 
Intracranial Atheromatous Disease all patients undergoing angi-
oplasty and stenting using the Gateway balloon–Wingspan stent 
system were prospectively followed (Fiorella et al., 2007). During 
a 9-month period, treatment with the Wingspan stent system was 
attempted in 78 patients with 82 intracranial atheromatous lesions, 
of which 54 were ≥70% stenotic. Eighty-one of 82 lesions were suc-
cessfully stented (98.8%) during the first treatment session with 
the other treated only with angioplasty and stented at a later date. 
The mean pretreatment stenosis was 74.6%, improving to 43.5% 
after balloon angioplasty and to 27.2% after stent placement. There 
were five (6.1%) major periprocedural neurological complications, 
four of which ultimately led to patient death within 30 days of the 
procedure. Diffusion-weighted MRI sequences were done on 38 
patients within 72 h of the procedure. Thirteen (34.2%) had new 
ischemic lesions with only three being symptomatic.
In the NIH Registry on the use of the Wingspan Stent for 
Symptomatic 70–99% Intracranial arterial stenosis 129 consecutive 
patients were enrolled (Zaidat et al., 2008). The technical success 
rate was 96.7%. The mean pre-stent stenosis was 82% reduced 
to 20% after stenting. The frequency of any stroke, intracerebral 
hemorrhage, or death within 30 days or ipsilateral stroke beyond 
30 days was 14% at 6 months. Any stroke or death occurred in eight 
patients (6.2%) within 24 h of treatment. Fifty-two patients (40%) 
had follow-up cerebral angiograms at a mean of 4.8 months. The 
mean residual stenosis was 29%, with 13 patients (25%) having 
restenosis ≥50%, and 2 patients had ischemic stokes with both 
attributed to stent occlusions.
The Wingspan SEIS is currently under study in SAMMPRIS to 
compare stenting with aggressive medical management.
comparIson of BeBms/des to seIs
Gröschel et al. (2009) conducted a systematic review 31 studies 
dealing with 1177 intracranial stenting procedures from 1998 
to 2008. Ninety-eight percent were performed in patients with a 
drug-elutIng stents
Some investigators have employed the use of drug-eluting stents 
(DES) to treat ICAD as have been used in the coronary vascula-
ture. DES have a coating of antiproliferative material that inhibits 
neointimal hyperplasia. Steinfort et al. (2007) reported a review of 
13 patients with symptomatic posterior circulation stenosis treated 
with pacilitaxel-coated stents. One patient suffered a periprocedural 
stroke, and nine patients had angiographic follow-up at a mean of 
5.4 months with no significant in-stent stenosis. Qureshi et al. (2006) 
treated 18 patients with either a sirolimus-eluting stent (n = 14) or 
a paclitaxel-eluting stent (n = 4) for symptomatic stenosis (≥70% 
or failed medical management). There was one major stroke and 
no death observed in the 1-month follow-up. Major stroke-free 
survival was 86% at 12 months. One symptomatic angiographic 
restenosis was observed during the follow-up period. Abou-Chebl 
et al. (2005) reviewed eight patients treated with DES with >70% 
stenoses that had failed maximal medical therapy. Patients were 
pretreated with aspirin and clopidogrel and these were contin-
ued after the procedure for 1 year. Eight patients with intracranial 
lesions: internal carotid artery (3), middle cerebral (2), basilar (2), 
and vertebral artery (1) stenoses were successfully treated with 4 
Cypher (Cordis Corp) and 4 Taxus (Boston Scientific) stents. The 
mean stenosis severity was reduced from 84.4 to 2.5%. One patient 
had an intraprocedural retinal embolism, but there were no other 
complications. Over a mean follow-up of 11 months, patients had 
repeat angiography (5) or transcranial Doppler with or without 
CT angiography (3). None of the patients had clinical or signifi-
cant angiographic restenosis. Likewise, Gupta et al. (2006) showed 
feasibility and safety by treating 62 symptomatic lesions, of which 
26 were ICAD, with DES (Cypher or Taxus). Intracranial stent-
ing was attempted in 29 but only successfully deployed in 26. At 
angiographic follow-up, 1 of 26 (5%) intracranial DES and 2 of 36 
extracranial DES were found to have restenosis ≥50% at a mean 
 follow-up of 4 months. The previous DES studies used first gen-
eration stents with sirolimus or paclitaxel. Natarajan et al. (2010) 
reported six patients with symptomatic ICAD treated with a sec-
ond generation DES that has greater deliverability. The Xience V 
everolimus-eluting stent (Abbott Vascular) was placed in six patients 
with >70% stenosis. Average stenosis was reduced from 83 to 6%. 
There was one post-intervention hemorrhage which required a 
craniectomy. Five of six patients had angiographic follow-up at 
5–6 months with no restenosis.
There is still insufficient data to recommend the safe and effec-
tive use of DES in the intracranial vasculature and more study is 
required. The ongoing concerns with DES is the need for prolonged 
use of dual antiplatelet therapy with aspirin and clopidrogel which 
may increase the risk of hemorrhage especially in the brain and 
late restenosis.
self-expandIng IntracranIal stents
The Wingspan stent system® (Boston Scientific) was the first self-
expanding intracranial stents (SEIS) to be approved for the treat-
ment of ICAD in patients with medically refractory disease under 
a humanitarian device exemption (HDE) in August 2005. This was 
approved after being studied in a prospective, multicenter, single-
arm intracranial stenting study for medically refractory patients 
in Europe and Asia (Bose et al., 2007). Forty-five patients with 
FiGuRe 1 | Right middle cerebral artery stenosis treated with SeiS/
Wingspan stent.
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 comparable to the NIH Wingspan registry (Zaidat et al., 2008; 
25%). Typically ISR is asymptomatic (76%) but it can cause neu-
rological symptoms (Levy et al., 2007). Thirty-six patients in the 
registry experienced in ISR after PTA and stenting with Wingspan. 
Of these patients, 29 (80.6%) have undergone target lesion revas-
cularization with either angioplasty alone (n = 26) or angioplasty 
with restenting (n = 3). Restenting was performed for in-stent 
dissections that occurred after the initial angioplasty. Of the 29 
patients undergoing target lesion revascularization, 9 required ≥ 1 
interventions for recurrent ISR, for a total of 42 interventions. One 
major complication, a post-procedural reperfusion hemorrhage, 
was encountered in the periprocedural period (2.4% per proce-
dure; 3.5% per patient). Angiographic follow-up was available for 
22 of 29 patients after target lesion revascularization. Eleven of 22 
(50%) demonstrated recurrent ISR at follow-up angiography. Nine 
patients had multiple retreatments for recurrence. Recurrent lesions 
were more common in the anterior circulation.
In-stent restenosis in most instances is asymptomatic and 
therefore its management and the need for retreatment with 
angioplasty and/or stenting is not clear. However most operators 
feel the need to retreat if the ISR causes a stenosis that is worse 
than the original lesion or the patient becomes symptomatic. 
Further study is required to identify patients at risk, potentially 
modifiable risk factors and methods of treatment of ISR after 
stenting of ICAD.
medIcal management compared to endovascular treatment
Patients from the WASID trial (254) and from the NIH Wingspan 
multicenter stent registry (158) were matched to determine the 
differential rate of stroke or death within 30 days or ipsilateral 
stroke beyond 30 days (Jarvis et al., 2008). They were divided into 
two categories of 50–69% and 70–99% stenosis. The primary event 
rates in WASID patients with 70–99% stenosis was 7 and 16%, 
respectively; the comparable rates in the Wingspan group were 
10 and 13%. There was no difference in the 50–69% groups. As 
mentioned previously, SAMMPRIS is an ongoing trial comparing 
stenting combined with best medical management to best medical 
management alone.
prImary angIoplasty compared to angIoplasty wIth stent 
placement
Siddiq et al. (2008) retrospectively analyzed the clinical and angi-
ographic data of 190 patients treated with 95 primary angioplasty 
procedures and 98 intracranial stent placements in three tertiary 
care centers. Fourteen procedures in the angioplasty-treated group 
(15%) and four in the stent-treated group (4%) had significant 
post-operative residual stenosis. There were 3 periprocedural deaths 
(1.5%), 1 in the angioplasty group (1%) and 2 in the stent-treated 
group (2.0%) and 14 periprocedural strokes (7.3%), 7 periproce-
dural strokes in each group (7.4 and 7.1%). Angiographic follow-up 
was available for 134 procedures (66 angioplasty-treated and 68 
stent-treated cases). Forty-eight patients had restenosis (25 of 66 
angioplasties, 23 of 68 stents). Restenosis-free survival at 12 months 
was 68% for the angioplasty-treated group and 64% for the stent-
treated group. There was no difference in follow-up survival (stroke, 
or stroke and/or death) between the angioplasty-treated and the 
stent-treated groups at 2 years.
 symptomatic high-grade (mean: 78%) intracranial stenosis. The 
median technical success rate was 96%. The periprocedural minor 
or major stroke and death rates ranged from 0 to 50% with a median 
of 7.7%. Periprocedural complications were significantly higher in 
the posterior (12.1%) versus the anterior circulation (6.6%), but 
did not differ between patients treated with a balloon-mounted 
versus those who had been treated with a self-expandable stent(s). 
However restenosis ≥50% occurred more frequently after the use of 
a self-expandable stent (17.4%, mean follow-up of 5.4 months) than 
a balloon-mounted stent (13.8%, mean follow-up of 8.7 months). 
This has been attributed to the higher amount of radial force 
applied to the vessel by BEBMS and that most SEIS are deployed 
after a submaximal angioplasty.
A comparison of stent design between coronary and cerebral 
stents can be seen in Figure 1.
restenosIs after angIoplasty and stentIng
Albuquerque et al. (2008) described in-stent restenosis (ISR) as 
>50% stenosis within or immediately adjacent (within 5 mm) to 
the implanted stent(s) and >20% absolute luminal loss. Imaging 
 follow-up (3–15.5 months) was available for 127 intracranial stenotic 
lesions treated with the Wingspan stent system. Forty-one lesions 
(32%) developed either ISR (28%) or complete stent occlusion (4%) 
after treatment. When restenotic lesions were characterized using the 
modified classification system, 25 of 41 (61.0%) were focal lesions 
involving <50% of the length of the stented segment: three were Type 
IA (focal stenosis involving one end of the stent), 21 were Type IB 
(focal intrastent stenosis involving a segment completely contained 
within the stent), and one was Type IC (multiple non-contiguous 
focal stenoses). Eleven lesions (26.8%) demonstrated diffuse stenosis 
(>50% of the length of the stented segment): nine were Type II with 
diffuse intrastent stenosis (completely contained within the stent) 
and two were Type III with proliferative in-stent stenosis (extending 
beyond the stented segment). Five stents were completely occluded 
at follow-up (Type IV). Of the 36 ISR lesions, 16 were less severe or 
no worse than the original lesion with respect to severity of stenosis 
or length of the segment involved. Twenty lesions were more severe 
than the original lesion. Supraclinoid internal carotid artery and 
middle cerebral artery lesions have a propensity to develop more 
severe post-treatment stenosis.
Levy et al. (2007) reported follow-up imaging (average duration, 
5.9 months) available for 84 lesions treated with the Wingspan 
stent (78 patients). Follow-up examinations consisted of 65 con-
ventional angiograms, 17 computed tomographic angiograms, and 
two magnetic resonance angiograms. ISR was documented in 25 
and complete thrombosis in 4 patients. Two of the four patients 
with stent thrombosis had lengthy lesions requiring more than 
one stent to bridge the diseased segment. ISR was more frequent 
in the anterior circulation (42%) than the posterior circulation 
(13%). Eight patients were symptomatic (four with stroke, four 
with transient ischemic attack) and 15 were retreated. Of these, 
four were complicated by clinically silent in-stent dissections, two 
of which required the placement of a second stent. One patient had 
a post-procedural reperfusion hemorrhage.
The ISR rate with the Wingspan stent is higher in the multi-
center experience Levy and colleagues (Fiorella et al., 2007; 30%) 
than in the original Wingspan study (Bose et al., 2007; 15%), but 
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